Credit Suisse Downgrades Esperion Therapeutics (ESPR) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Credit Suisse Downgrades Esperion Therapeutics (ESPR) to Neutral
October 18, 2021 7:00 AM EDT
Optimizes organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes trial
Reduces overall workforce by 40 percent and further shifts marketing strategy towards a greater proportion of digital and virtual outreach
Significant operational expense reductions expected in FY 2021 & FY 2022; estimated annualized cash savings of at least $80 million
ANN ARBOR, Mich., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its plan to align... More
October 18, 2021 7:00 AM EDT
Optimizes organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes trial
Reduces overall workforce by 40 percent and further shifts marketing strategy towards a greater proportion of digital and virtual outreach
Significant operational expense reductions expected in FY 2021 & FY 2022; estimated annualized cash savings of at least $80 million
ANN ARBOR, Mich., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its plan to align... More
